From new findings in acne pathogenesis to new approaches in treatment
Acne is a chronic disease of the pilosebaceous unit which is most common during adolescence. Four factors are believed to play a key role in the development of acne lesions: excess sebum production, disturbed keratinization within the follicle, colonization of the pilosebaceous duct by Propionibacte...
Saved in:
Published in: | Journal of the European Academy of Dermatology and Venereology Vol. 29; no. S5; pp. 1 - 7 |
---|---|
Main Author: | |
Format: | Journal Article |
Language: | English |
Published: |
England
Blackwell Publishing Ltd
01-06-2015
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Acne is a chronic disease of the pilosebaceous unit which is most common during adolescence. Four factors are believed to play a key role in the development of acne lesions: excess sebum production, disturbed keratinization within the follicle, colonization of the pilosebaceous duct by Propionibacterium acnes, and the release of inflammatory mediators into the skin. Consequently, in order to effectively and rapidly reduce acne lesions, treatments need to address as many of these underlying factors as possible. Currently, about half of patients have poor adherence to acne treatments. To overcome this limitation, treatments need to be developed which are well tolerated by patients, and easy for them to use, handle and apply. Topical monotherapies for acne such as retinoids and antimicrobials by themselves have a restricted range of actions against the pathogenic factors of acne. Instead, the Global Alliance to Improve Outcomes in Acne Group recommends combination therapy with a topical retinoid and an antimicrobial agent as the preferred approach for almost all acne patients. The principal advantage of such combinations is that they target more of the underlying pathogenic factors of acne than individual monotherapies and this results in faster and more complete clearing of acne lesions. Fixed‐dose combinations are also more convenient than applying two medications separately, which leads to improved adherence with the regimen. By normalizing desquamation, the retinoid component of these combinations allows entry of the antimicrobial agent into the pilosebaceous unit resulting in faster clearance of P. acnes. In conclusion, topical retinoid/antimicrobial fixed‐dose combinations represent a rational approach for the treatment of acne. They should be considered as the cornerstone of acne management and should be used much more in the future. |
---|---|
AbstractList | Acne is a chronic disease of the pilosebaceous unit which is most common during adolescence. Four factors are believed to play a key role in the development of acne lesions: excess sebum production, disturbed keratinization within the follicle, colonization of the pilosebaceous duct by Propionibacterium acnes, and the release of inflammatory mediators into the skin. Consequently, in order to effectively and rapidly reduce acne lesions, treatments need to address as many of these underlying factors as possible. Currently, about half of patients have poor adherence to acne treatments. To overcome this limitation, treatments need to be developed which are well tolerated by patients, and easy for them to use, handle and apply. Topical monotherapies for acne such as retinoids and antimicrobials by themselves have a restricted range of actions against the pathogenic factors of acne. Instead, the Global Alliance to Improve Outcomes in Acne Group recommends combination therapy with a topical retinoid and an antimicrobial agent as the preferred approach for almost all acne patients. The principal advantage of such combinations is that they target more of the underlying pathogenic factors of acne than individual monotherapies and this results in faster and more complete clearing of acne lesions. Fixed-dose combinations are also more convenient than applying two medications separately, which leads to improved adherence with the regimen. By normalizing desquamation, the retinoid component of these combinations allows entry of the antimicrobial agent into the pilosebaceous unit resulting in faster clearance of P. acnes. In conclusion, topical retinoid/antimicrobial fixed-dose combinations represent a rational approach for the treatment of acne. They should be considered as the cornerstone of acne management and should be used much more in the future. Acne is a chronic disease of the pilosebaceous unit which is most common during adolescence. Four factors are believed to play a key role in the development of acne lesions: excess sebum production, disturbed keratinization within the follicle, colonization of the pilosebaceous duct by Propionibacterium acnes, and the release of inflammatory mediators into the skin. Consequently, in order to effectively and rapidly reduce acne lesions, treatments need to address as many of these underlying factors as possible. Currently, about half of patients have poor adherence to acne treatments. To overcome this limitation, treatments need to be developed which are well tolerated by patients, and easy for them to use, handle and apply. Topical monotherapies for acne such as retinoids and antimicrobials by themselves have a restricted range of actions against the pathogenic factors of acne. Instead, the Global Alliance to Improve Outcomes in Acne Group recommends combination therapy with a topical retinoid and an antimicrobial agent as the preferred approach for almost all acne patients. The principal advantage of such combinations is that they target more of the underlying pathogenic factors of acne than individual monotherapies and this results in faster and more complete clearing of acne lesions. Fixed‐dose combinations are also more convenient than applying two medications separately, which leads to improved adherence with the regimen. By normalizing desquamation, the retinoid component of these combinations allows entry of the antimicrobial agent into the pilosebaceous unit resulting in faster clearance of P. acnes . In conclusion, topical retinoid/antimicrobial fixed‐dose combinations represent a rational approach for the treatment of acne. They should be considered as the cornerstone of acne management and should be used much more in the future. |
Author | Gollnick, H. P. M. |
Author_xml | – sequence: 1 givenname: H. P. M. surname: Gollnick fullname: Gollnick, H. P. M. email: harald.gollnick@med.ovgu.de organization: Department of Dermatology & Venereology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26059819$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kMtOwzAQRS1UBG1hwQ-gLGER6qljx16iUl6qipCgLC0nGUNK4pQ4Bfr3hD7YMZvRSOdejU6PdFzlkJAToBfQzmCefV4AAyn2SBciIUNGJeuQLlVDESrF1SHpeT-nlAJweUAOh4JyJUF1yfi6rsrA4Vdgc5fl7tUHuQtM6jBYmOatekWHPvdBU60hs1jUlUnfcI01NZqmRNcckX1rCo_H290nz9fjp9FtOHm4uRtdTsKUKSnCaMjSxFjDpY2MiblqjzhjEQWbgE2FVBRogpkCq2IrFVoGlmIaUaPokCPrk7NNb_vFxxJ9o8vcp1gUxmG19BqEjAWHiPIWPd-gaV15X6PVizovTb3SQPWvNd1a02trLXu6rV0mJWZ_5E5TCww2wFde4Or_Jn1_NdtVhptE7hv8_kuY-l2LmMVcv0xv9Gz6OOEAsY7YD9oKh1s |
CitedBy_id | crossref_primary_10_1080_09546634_2019_1654075 crossref_primary_10_1155_2020_2857812 crossref_primary_10_15171_apb_2019_067 crossref_primary_10_15171_apb_2019_066 crossref_primary_10_17816_dv625969 crossref_primary_10_25208_vdv16050 crossref_primary_10_58600_eurjther2220 crossref_primary_10_2147_CCID_S426451 crossref_primary_10_1111_jocd_12227 crossref_primary_10_1111_ddg_13664_g crossref_primary_10_25208_0042_4609_2016_92_2_81_86 crossref_primary_10_17816_pmj3945_10 crossref_primary_10_1111_ddg_13278 crossref_primary_10_5694_mja16_00516 crossref_primary_10_1111_ddg_13048_e crossref_primary_10_20473_jbe_V9I32021_257_265 crossref_primary_10_1111_1440_1681_13552 crossref_primary_10_1111_ddg_30_13278 crossref_primary_10_1080_15569527_2016_1237521 crossref_primary_10_1111_jdv_16634 crossref_primary_10_3390_jcm11061507 crossref_primary_10_25208_0042_4609_2019_95_1_77_81 crossref_primary_10_1007_s00403_019_01932_x crossref_primary_10_1111_bjd_17721 crossref_primary_10_2174_0122103031246178231001111944 crossref_primary_10_3389_fcimb_2020_575164 crossref_primary_10_1021_acs_jafc_3c04617 crossref_primary_10_1111_ddg_13048 crossref_primary_10_1111_jdv_13579 crossref_primary_10_33667_2078_5631_2022_27_67_72 crossref_primary_10_7717_peerj_13553 crossref_primary_10_17816_pmj39611_16 crossref_primary_10_17816_pmj39224_28 crossref_primary_10_1055_s_0040_1713792 crossref_primary_10_1080_09546634_2019_1692125 crossref_primary_10_1111_jocd_12367 crossref_primary_10_1080_07853890_2023_2207038 crossref_primary_10_2478_amma_2020_0001 crossref_primary_10_1111_jocd_13498 crossref_primary_10_1111_jocd_15676 crossref_primary_10_1155_2022_3644720 crossref_primary_10_25208_vdv1157 crossref_primary_10_3390_pharmaceutics13111930 crossref_primary_10_3390_jcm11133660 crossref_primary_10_1111_jdv_14491 crossref_primary_10_5604_01_3001_0014_9855 crossref_primary_10_1080_09546634_2019_1628173 crossref_primary_10_1002_fsn3_4054 crossref_primary_10_1111_jocd_13497 crossref_primary_10_3390_nu14142980 crossref_primary_10_4103_MJBL_MJBL_88_22 crossref_primary_10_1111_ddg_13664 crossref_primary_10_15406_jdc_2023_07_00224 crossref_primary_10_21682_2311_1267_2023_10_1_73_80 crossref_primary_10_1111_jdv_13675 crossref_primary_10_1155_2022_2011945 crossref_primary_10_3390_ijms23073589 crossref_primary_10_33667_2078_5631_2023_8_53_63 crossref_primary_10_17816_pmj412136_141 crossref_primary_10_1111_1346_8138_14314 |
Cites_doi | 10.4049/jimmunol.169.3.1535 10.1046/j.1365-2133.1998.1390s2048.x 10.1684/ejd.2014.2309 10.1016/j.jaad.2007.05.013 10.2165/00128071-200809050-00001 10.1111/j.1468-3083.2011.04374.x 10.1136/bmj.298.6682.1217 10.1111/jdv.12160 10.1542/peds.2005-2022 10.4103/0378-6323.34010 10.2165/00003495-200464210-00002 10.1046/j.1365-2133.1998.1390s3004.x 10.1210/edrv.21.4.0404 10.1046/j.1365-2133.2001.04276.x 10.1111/j.1365-4632.2009.04270.x 10.1111/1523-1747.ep12329907 10.1001/archderm.1969.01610220097017 10.1016/j.jaad.2007.06.045 10.1111/j.1468-3083.2007.02190.x 10.1111/j.1365-4632.2010.04416.x 10.1111/bjd.12149 10.1111/j.1365-2133.2005.06614.x 10.1016/j.jaad.2009.01.019 10.1067/mjd.2003.618 10.1111/j.1365-2133.2005.06933.x 10.4049/jimmunol.174.5.2467 10.1111/j.1365-2133.2005.07047.x 10.1111/jdv.12224 10.1046/j.1365-2133.1998.1390s2008.x 10.1093/jac/dkm408 10.1016/j.clinthera.2005.02.009 10.1111/j.1365-2133.2012.10897.x 10.1046/j.1365-2133.2000.03531.x 10.1111/j.1346-8138.1991.tb03122.x 10.1067/S0190-9622(03)01154-X 10.1046/j.1365-2133.2003.05067.x 10.1016/S0140-6736(11)60321-8 10.1111/j.1525-1470.2008.00667.x 10.1016/j.biocel.2009.11.017 10.1111/1523-1747.ep12616181 10.1517/14656560903277228 10.1038/jid.2013.334 10.1371/journal.pone.0012277 10.1080/000155502320323216 |
ContentType | Journal Article |
Copyright | 2015 European Academy of Dermatology and Venereology 2015 European Academy of Dermatology and Venereology. |
Copyright_xml | – notice: 2015 European Academy of Dermatology and Venereology – notice: 2015 European Academy of Dermatology and Venereology. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1111/jdv.13186 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-3083 |
EndPage | 7 |
ExternalDocumentID | 10_1111_jdv_13186 26059819 JDV13186 ark_67375_WNG_VNQL5117_4 |
Genre | reviewArticle Journal Article Review |
GrantInformation_xml | – fundername: Meda Pharma GmbH & Co. KG |
GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OB 1OC 1~5 29L 31~ 33P 36B 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADZMN AE3 AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFTJW AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG CO8 COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ NQ- O66 O9- OIG OVD OZT P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K R2- RIG RIWAO RJQFR ROL RPZ RX1 SAMSI SEW SUPJJ TEORI UB1 UHS W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c3986-423cbafa58f4aa759baf7d3401fb1fc689010bed91f97f89ef31f0ec40a9025e3 |
IEDL.DBID | 33P |
ISSN | 0926-9959 |
IngestDate | Fri Aug 16 10:10:32 EDT 2024 Fri Nov 22 01:08:43 EST 2024 Sat Sep 28 07:56:26 EDT 2024 Sat Aug 24 00:55:22 EDT 2024 Wed Oct 30 09:50:22 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S5 |
Language | English |
License | 2015 European Academy of Dermatology and Venereology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3986-423cbafa58f4aa759baf7d3401fb1fc689010bed91f97f89ef31f0ec40a9025e3 |
Notes | Meda Pharma GmbH & Co. KG istex:14D619EC0A2757AF8EA079F80689CD701F44BDFB ArticleID:JDV13186 ark:/67375/WNG-VNQL5117-4 This supplement was funded by Meda Pharma GmbH & Co. KG. HG has been, over the last decade, a speaker at several symposia sponsored by Meda, Galderma, Roche‐Posay, Intendis, GSK, Hermal‐Almiral. He was invited to attend advisory boards of Galderma, Meda, Novartis, Intendis, Hermal‐Almirall. Conflict of interest Funding source ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.13186 |
PMID | 26059819 |
PQID | 1687651405 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1687651405 crossref_primary_10_1111_jdv_13186 pubmed_primary_26059819 wiley_primary_10_1111_jdv_13186_JDV13186 istex_primary_ark_67375_WNG_VNQL5117_4 |
PublicationCentury | 2000 |
PublicationDate | 2015-06 June 2015 2015-Jun 2015-06-00 20150601 |
PublicationDateYYYYMMDD | 2015-06-01 |
PublicationDate_xml | – month: 06 year: 2015 text: 2015-06 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of the European Academy of Dermatology and Venereology |
PublicationTitleAlternate | J Eur Acad Dermatol Venereol |
PublicationYear | 2015 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989; 298: 1217-1219. Thielitz A, Helmdach M, Roepke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19-27. Karciauskiene J, Valiukeviciene S, Gollnick H, Stang A. The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross-sectional study. J Eur Acad Dermatol Venereol 2014; 28: 733-740. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49: S200-S210. Krakowski AC, Stendardo S, Eichenfield LF. Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatr Dermatol 2008; 25(Suppl. 1): 1-14. Jahns AC, Lundskog B, Ganceviciene R et al. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study. Br J Dermatol 2012; 167: 50-58. Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992; 99: 509-511. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106: 176-182. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21: 747-753. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 2009; 10: 2555-2562. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991; 18: 489-499. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361-372. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467-2470. Jugeau S, Tenaud I, Knol AC et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005; 153: 1105-1113. Collier CN, Harper JC, Cafardi JA et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008; 58: 56-59. Del Rosso JQ, Jitpraphai W, Bhambri S, Momin S. Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability. Cutis 2008; 81: 405-408. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol 2007; 57: 722-724. Dreno B, Thiboutot D, Gollnick H et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010; 49: 448-456. Valins W, Amini S, Berman B. The expression of Toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll-like receptor modulators. J Clin Aesthet Dermatol 2010; 3: 20-29. Bayston R, Nuradeen B, Ashraf W, Freeman BJ. Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother 2007; 60: 1298-1301. Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS ONE 2010; 5: e12277. Jain GK, Ahmed FJ. Adapalene pretreatment increases follicular penetration of clindamycin: in vitro and in vivo studies. Indian J Dermatol Venereol Leprol 2007; 73: 326-329. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084-1091. Pawin H, Beylot C, Chivot M et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14: 4-12. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389-2397. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(Suppl. 53): 4-8. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis 2006; 77: 45-50. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524-532. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26(Suppl. 1): 1-29. Beylot C, Auffret N, Poli F et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014; 28: 271-278. Dreno B, Thiboutot D, Gollnick H et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330-334. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21: 363-392. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99: 469-476. Dumont-Wallon G, Moyse D, Blouin E, Dreno B. Bacterial resistance in French acne patients. Int J Dermatol 2010; 49: 283-288. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1-S37. Schneider MR, Paus R. Sebocytes, multifaceted epithelial cells: lipid production and holocrine secretion. Int J Biochem Cell Biol 2010; 42: 181-185. Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279-284. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006; 118: 1188-1199. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260-265. Agak GW, Qin M, Nobe J et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest Dermatol 2014; 134: 366-373. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474-485. Kircik LH. Microsphere technology: hype or help? J Clin Aesthet Dermatol 2011; 4: 27-31. Kim J, Ochoa MT, Krutzik SR et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(Suppl. 52):48-56. Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 2010; 85: 15-24. Yentzer BA, Ade RA, Fountain JM et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010; 86: 103-108. Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther 2005; 27: 216-224. Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: S1-S50. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139(Suppl. 52): 8-11. Ross JI, Snelling AM, Carnegie E et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467-478. Schmidt N, Gans EH. Tretinoin: A review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol 2011; 4: 22-29. 1991; 18 2004; 64 2001; 145 2012; 167 2005; 174 2005; 153 2011 2009; 60 2006; 77 2000; 21 1989; 298 2008; 9 2008; 58 1969; 99 2006; 154 2013; 168 2014; 24 2002; 82 1998; 139 2007; 73 2014; 28 2011; 4 2005; 27 2006; 118 1992; 99 2007; 57 2010; 85 2014; 134 1996; 106 2010; 42 2010; 86 2010; 49 2009; 10 2004; 14 2002; 169 2008; 25 2003; 49 2000; 142 2007; 60 2012; 26 2010; 3 2003; 148 2012; 379 2007; 21 2010; 5 2008; 81 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 Del Rosso JQ (e_1_2_8_43_1) 2010; 85 Kircik LH (e_1_2_8_38_1) 2011; 4 e_1_2_8_3_1 Schmidt N (e_1_2_8_33_1) 2011; 4 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_15_1 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 Valins W (e_1_2_8_17_1) 2010; 3 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 Del Rosso JQ (e_1_2_8_37_1) 2008; 81 e_1_2_8_44_1 Pawin H (e_1_2_8_20_1) 2004; 14 e_1_2_8_40_1 e_1_2_8_18_1 Grimes P (e_1_2_8_35_1) 2006; 77 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_16_1 Yentzer BA (e_1_2_8_51_1) 2010; 86 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_12_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
References_xml | – volume: 142 start-page: 1084 year: 2000 end-page: 1091 article-title: Comedogenesis: some new aetiological, clinical and therapeutic strategies publication-title: Br J Dermatol – volume: 49 start-page: 283 year: 2010 end-page: 288 article-title: Bacterial resistance in French acne patients publication-title: Int J Dermatol – year: 2011 – volume: 139 start-page: 48 issue: Suppl. 52 year: 1998 end-page: 56 article-title: A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta‐analysis of five randomized trials publication-title: Br J Dermatol – volume: 5 start-page: e12277 year: 2010 article-title: Population genetic analysis of identifies a subpopulation and epidemic clones associated with acne publication-title: PLoS ONE – volume: 82 start-page: 260 year: 2002 end-page: 265 article-title: Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle publication-title: Acta Derm Venereol – volume: 4 start-page: 27 year: 2011 end-page: 31 article-title: Microsphere technology: hype or help? publication-title: J Clin Aesthet Dermatol – volume: 3 start-page: 20 year: 2010 end-page: 29 article-title: The expression of Toll‐like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll‐like receptor modulators publication-title: J Clin Aesthet Dermatol – volume: 86 start-page: 103 year: 2010 end-page: 108 article-title: Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial publication-title: Cutis – volume: 49 start-page: S200 year: 2003 end-page: S210 article-title: A review of the use of combination therapies for the treatment of acne vulgaris publication-title: J Am Acad Dermatol – volume: 99 start-page: 469 year: 1969 end-page: 476 article-title: Topical vitamin A acid in acne vulgaris publication-title: Arch Dermatol – volume: 169 start-page: 1535 year: 2002 end-page: 1541 article-title: Activation of toll‐like receptor 2 in acne triggers inflammatory cytokine responses publication-title: J Immunol – volume: 81 start-page: 405 year: 2008 end-page: 408 article-title: Clindamycin phosphate 1.2%‐ tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability publication-title: Cutis – volume: 379 start-page: 361 year: 2012 end-page: 372 article-title: Acne vulgaris publication-title: Lancet – volume: 14 start-page: 4 year: 2004 end-page: 12 article-title: Physiopathology of acne vulgaris: recent data, new understanding of the treatments publication-title: Eur J Dermatol – volume: 4 start-page: 22 year: 2011 end-page: 29 article-title: Tretinoin: A review of its anti‐inflammatory properties in the treatment of acne publication-title: J Clin Aesthet Dermatol – volume: 73 start-page: 326 year: 2007 end-page: 329 article-title: Adapalene pretreatment increases follicular penetration of clindamycin: in vitro and in vivo studies publication-title: Indian J Dermatol Venereol Leprol – volume: 28 start-page: 733 year: 2014 end-page: 740 article-title: The prevalence and risk factors of adolescent acne among schoolchildren in Lithuania: a cross‐sectional study publication-title: J Eur Acad Dermatol Venereol – volume: 153 start-page: 395 year: 2005 end-page: 403 article-title: Treatment of acne with topical antibiotics: lessons from clinical studies publication-title: Br J Dermatol – volume: 18 start-page: 489 year: 1991 end-page: 499 article-title: Pathogenesis and pathogenesis related treatment of acne publication-title: J Dermatol – volume: 58 start-page: 56 year: 2008 end-page: 59 article-title: The prevalence of acne in adults 20 years and older publication-title: J Am Acad Dermatol – volume: 28 start-page: 271 year: 2014 end-page: 278 article-title: : an update on its role in the pathogenesis of acne publication-title: J Eur Acad Dermatol Venereol – volume: 148 start-page: 467 year: 2003 end-page: 478 article-title: Antibiotic‐resistant acne: lessons from Europe publication-title: Br J Dermatol – volume: 145 start-page: 19 year: 2001 end-page: 27 article-title: Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents publication-title: Br J Dermatol – volume: 10 start-page: 2555 year: 2009 end-page: 2562 article-title: Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris publication-title: Expert Opin Pharmacother – volume: 60 start-page: 1298 year: 2007 end-page: 1301 article-title: Antibiotics for the eradication of biofilms in surgical infection publication-title: J Antimicrob Chemother – volume: 134 start-page: 366 year: 2014 end-page: 373 article-title: induces an IL‐17 response in acne vulgaris that is regulated by vitamin A and vitamin D publication-title: J Invest Dermatol – volume: 57 start-page: 722 year: 2007 end-page: 724 article-title: Expanding the microcomedone theory and acne therapeutics: biofilm produces biological glue that holds corneocytes together to form plug publication-title: J Am Acad Dermatol – volume: 21 start-page: 363 year: 2000 end-page: 392 article-title: Role of hormones in pilosebaceous unit development publication-title: Endocr Rev – volume: 139 start-page: 4 issue: Suppl. 53 year: 1998 end-page: 8 article-title: Resistance to antibiotics used in dermatological practice publication-title: Br J Dermatol – volume: 139 start-page: 8 issue: Suppl. 52 year: 1998 end-page: 11 article-title: Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation publication-title: Br J Dermatol – volume: 42 start-page: 181 year: 2010 end-page: 185 article-title: Sebocytes, multifaceted epithelial cells: lipid production and holocrine secretion publication-title: Int J Biochem Cell Biol – volume: 26 start-page: 1 issue: Suppl. 1 year: 2012 end-page: 29 article-title: European evidence‐based (S3) guidelines for the treatment of acne publication-title: J Eur Acad Dermatol Venereol – volume: 60 start-page: S1 year: 2009 end-page: S50 article-title: New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group publication-title: J Am Acad Dermatol – volume: 64 start-page: 2389 year: 2004 end-page: 2397 article-title: Topical antibacterial therapy for acne vulgaris publication-title: Drugs – volume: 153 start-page: 1105 year: 2005 end-page: 1113 article-title: Induction of toll‐like receptors by publication-title: Br J Dermatol – volume: 24 start-page: 330 year: 2014 end-page: 334 article-title: Antibiotic stewardship in dermatology: limiting antibiotic use in acne publication-title: Eur J Dermatol – volume: 49 start-page: S1 year: 2003 end-page: S37 article-title: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne publication-title: J Am Acad Dermatol – volume: 154 start-page: 524 year: 2006 end-page: 532 article-title: Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial publication-title: Br J Dermatol – volume: 49 start-page: 448 year: 2010 end-page: 456 article-title: Large‐scale worldwide observational study of adherence with acne therapy publication-title: Int J Dermatol – volume: 25 start-page: 1 issue: Suppl. 1 year: 2008 end-page: 14 article-title: Practical considerations in acne treatment and the clinical impact of topical combination therapy publication-title: Pediatr Dermatol – volume: 174 start-page: 2467 year: 2005 end-page: 2470 article-title: Cutting edge: all‐trans retinoic acid down‐regulates TLR2 expression and function publication-title: J Immunol – volume: 21 start-page: 747 year: 2007 end-page: 753 article-title: Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1% publication-title: J Eur Acad Dermatol Venereol – volume: 9 start-page: 279 year: 2008 end-page: 284 article-title: Can we define acne as a chronic disease? If so, how and when? publication-title: Am J Clin Dermatol – volume: 168 start-page: 474 year: 2013 end-page: 485 article-title: Epidemiology of acne vulgaris publication-title: Br J Dermatol – volume: 106 start-page: 176 year: 1996 end-page: 182 article-title: Modeling acne in vitro publication-title: J Invest Dermatol – volume: 85 start-page: 15 year: 2010 end-page: 24 article-title: A review of the anti‐inflammatory properties of clindamycin in the treatment of acne vulgaris publication-title: Cutis – volume: 118 start-page: 1188 year: 2006 end-page: 1199 article-title: Expert committee recommendations for acne management publication-title: Pediatrics – volume: 77 start-page: 45 year: 2006 end-page: 50 article-title: Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double‐blind, randomized, vehicle‐controlled study publication-title: Cutis – volume: 167 start-page: 50 year: 2012 end-page: 58 article-title: An increased incidence of biofilms in acne vulgaris: a case‐control study publication-title: Br J Dermatol – volume: 298 start-page: 1217 year: 1989 end-page: 1219 article-title: Acne in schoolchildren: no longer a concern for dermatologists publication-title: BMJ – volume: 99 start-page: 509 year: 1992 end-page: 511 article-title: Control of human sebocyte proliferation in vitro by testosterone and 5‐alpha‐dihydrotestosterone is dependent on the localization of the sebaceous glands publication-title: J Invest Dermatol – volume: 27 start-page: 216 year: 2005 end-page: 224 article-title: Topical retinoids in inflammatory acne: a retrospective, investigator‐blinded, vehicle‐controlled, photographic assessment publication-title: Clin Ther – ident: e_1_2_8_18_1 doi: 10.4049/jimmunol.169.3.1535 – ident: e_1_2_8_36_1 doi: 10.1046/j.1365-2133.1998.1390s2048.x – ident: e_1_2_8_44_1 doi: 10.1684/ejd.2014.2309 – ident: e_1_2_8_25_1 doi: 10.1016/j.jaad.2007.05.013 – volume: 4 start-page: 27 year: 2011 ident: e_1_2_8_38_1 article-title: Microsphere technology: hype or help? publication-title: J Clin Aesthet Dermatol contributor: fullname: Kircik LH – ident: e_1_2_8_3_1 doi: 10.2165/00128071-200809050-00001 – ident: e_1_2_8_14_1 doi: 10.1111/j.1468-3083.2011.04374.x – ident: e_1_2_8_4_1 doi: 10.1136/bmj.298.6682.1217 – volume: 3 start-page: 20 year: 2010 ident: e_1_2_8_17_1 article-title: The expression of Toll‐like receptors in dermatological diseases and the therapeutic effect of current and newer topical Toll‐like receptor modulators publication-title: J Clin Aesthet Dermatol contributor: fullname: Valins W – ident: e_1_2_8_54_1 – ident: e_1_2_8_5_1 doi: 10.1111/jdv.12160 – ident: e_1_2_8_9_1 doi: 10.1542/peds.2005-2022 – volume: 85 start-page: 15 year: 2010 ident: e_1_2_8_43_1 article-title: A review of the anti‐inflammatory properties of clindamycin in the treatment of acne vulgaris publication-title: Cutis contributor: fullname: Del Rosso JQ – ident: e_1_2_8_52_1 doi: 10.4103/0378-6323.34010 – ident: e_1_2_8_41_1 doi: 10.2165/00003495-200464210-00002 – ident: e_1_2_8_47_1 doi: 10.1046/j.1365-2133.1998.1390s3004.x – ident: e_1_2_8_13_1 doi: 10.1210/edrv.21.4.0404 – ident: e_1_2_8_42_1 doi: 10.1046/j.1365-2133.2001.04276.x – ident: e_1_2_8_46_1 doi: 10.1111/j.1365-4632.2009.04270.x – ident: e_1_2_8_22_1 doi: 10.1111/1523-1747.ep12329907 – volume: 77 start-page: 45 year: 2006 ident: e_1_2_8_35_1 article-title: Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double‐blind, randomized, vehicle‐controlled study publication-title: Cutis contributor: fullname: Grimes P – ident: e_1_2_8_39_1 doi: 10.1001/archderm.1969.01610220097017 – ident: e_1_2_8_7_1 doi: 10.1016/j.jaad.2007.06.045 – ident: e_1_2_8_31_1 doi: 10.1111/j.1468-3083.2007.02190.x – ident: e_1_2_8_29_1 doi: 10.1111/j.1365-4632.2010.04416.x – ident: e_1_2_8_6_1 doi: 10.1111/bjd.12149 – volume: 14 start-page: 4 year: 2004 ident: e_1_2_8_20_1 article-title: Physiopathology of acne vulgaris: recent data, new understanding of the treatments publication-title: Eur J Dermatol contributor: fullname: Pawin H – ident: e_1_2_8_49_1 doi: 10.1111/j.1365-2133.2005.06614.x – ident: e_1_2_8_8_1 doi: 10.1016/j.jaad.2009.01.019 – volume: 4 start-page: 22 year: 2011 ident: e_1_2_8_33_1 article-title: Tretinoin: A review of its anti‐inflammatory properties in the treatment of acne publication-title: J Clin Aesthet Dermatol contributor: fullname: Schmidt N – ident: e_1_2_8_53_1 doi: 10.1067/mjd.2003.618 – ident: e_1_2_8_21_1 doi: 10.1111/j.1365-2133.2005.06933.x – ident: e_1_2_8_34_1 doi: 10.4049/jimmunol.174.5.2467 – ident: e_1_2_8_28_1 doi: 10.1111/j.1365-2133.2005.07047.x – ident: e_1_2_8_16_1 doi: 10.1111/jdv.12224 – ident: e_1_2_8_40_1 doi: 10.1046/j.1365-2133.1998.1390s2008.x – ident: e_1_2_8_24_1 doi: 10.1093/jac/dkm408 – ident: e_1_2_8_30_1 doi: 10.1016/j.clinthera.2005.02.009 – ident: e_1_2_8_23_1 doi: 10.1111/j.1365-2133.2012.10897.x – volume: 86 start-page: 103 year: 2010 ident: e_1_2_8_51_1 article-title: Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial publication-title: Cutis contributor: fullname: Yentzer BA – ident: e_1_2_8_15_1 doi: 10.1046/j.1365-2133.2000.03531.x – ident: e_1_2_8_10_1 doi: 10.1111/j.1346-8138.1991.tb03122.x – ident: e_1_2_8_32_1 doi: 10.1067/S0190-9622(03)01154-X – ident: e_1_2_8_45_1 doi: 10.1046/j.1365-2133.2003.05067.x – ident: e_1_2_8_2_1 doi: 10.1016/S0140-6736(11)60321-8 – ident: e_1_2_8_27_1 doi: 10.1111/j.1525-1470.2008.00667.x – ident: e_1_2_8_12_1 doi: 10.1016/j.biocel.2009.11.017 – ident: e_1_2_8_11_1 doi: 10.1111/1523-1747.ep12616181 – ident: e_1_2_8_50_1 doi: 10.1517/14656560903277228 – volume: 81 start-page: 405 year: 2008 ident: e_1_2_8_37_1 article-title: Clindamycin phosphate 1.2%‐ tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability publication-title: Cutis contributor: fullname: Del Rosso JQ – ident: e_1_2_8_19_1 doi: 10.1038/jid.2013.334 – ident: e_1_2_8_26_1 doi: 10.1371/journal.pone.0012277 – ident: e_1_2_8_48_1 doi: 10.1080/000155502320323216 |
SSID | ssj0001158 |
Score | 2.4754229 |
SecondaryResourceType | review_article |
Snippet | Acne is a chronic disease of the pilosebaceous unit which is most common during adolescence. Four factors are believed to play a key role in the development of... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1 |
SubjectTerms | Acne Vulgaris - drug therapy Acne Vulgaris - etiology Acne Vulgaris - pathology Acne Vulgaris - physiopathology Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Benzoyl Peroxide - therapeutic use Dermatologic Agents - administration & dosage Dermatologic Agents - therapeutic use Drug Combinations Humans Keratinocytes - pathology Photochemotherapy Retinoids - administration & dosage Retinoids - therapeutic use Treatment Outcome |
Title | From new findings in acne pathogenesis to new approaches in treatment |
URI | https://api.istex.fr/ark:/67375/WNG-VNQL5117-4/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdv.13186 https://www.ncbi.nlm.nih.gov/pubmed/26059819 https://search.proquest.com/docview/1687651405 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED90gvji90f9ooqIL5X0u8UncZtDdCjq9C2kTTKG2Mq6Df98L-laHCgIvrVwDeFyd_ld7_ILwAnmPCFP0gCRW4IJSuRwKyG-bwUBGoBDPJlK9U-38xh2X6NmS9HkXFRnYUp-iPqHm_IMHa-Vg7Ok-O7kfHJuo0Uqum3MEvTxDfe-jsKIdHQUjp3AUpxaU1Yh3cVTfTmzFy0otX7-BDRncaveeNor_5ryKixP8aZ5WRrIGsyJbB0W76YV9Q1otYf5u4nY2tTV66xfmIPMZGkmTHVZcd5XsXBQmKNcC1UU5EKL1V3qm_Dcbj1ddazp1QpW6sZRYCGIShMmmR9Jj7HQj_El5C4mWzKxZRpEqmsjETy2ZRzKKBbStSURqUeYqksKdwsaWZ6JHTC5GxFJiHAShrm2CBBvpRwHQWQXMjtmBhxXSqYfJYMGrTMPPqFaIQacavXXEmz4plrOQp--dK9pr_twi8gwpJ4BR9X6UHQEVd1gmcjHBbUDDOwI_4hvwHa5cPVoKmmLEfsYcKbX5_eJ0JtmTz_s_l10D5YQRvllA9k-NEbDsTiA-YKPD7VNfgGdMOCu |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB50F9QX76OeVUR8qbTbNm3BF9FdV91dFM-3kDbJsoit7IU_30m6LQoKgm8tTEKYK99kJhOAQ4x5Ah4nBJFbjAFKWONWbPu-RQgqQM32ZCLVmW7zPui8hBd11SbntLgLk_eHKA_clGVof60MXB1If7VyPj5xUCXJNFQ9goqoLnC4t6UfRqyj_XBUI5bqqjXpK6TreIqh33ajqmLsx09Q8zty1VtPY-F_i16E-QnkNM9yHVmCKZEuw0x7klRfgXqjn72ZCK9NncBOuwOzl5osSYWp3ivOusod9gbmMNNERRdyocnKQvVVeGzUH86b1uR1BStxo5BYiKOSmEnmh9JjLPAj_Am4i_GWjB2ZkFAVbsSCR46MAhlGQrqOtEXi2UylJoW7BpU0S8UGmNwNbWnbohYzDLcFQciVcJwEwV3AnIgZcFBwmb7nTTRoGXzwMdUMMeBI87-kYP1XVXUW-PS5c0mfOnctBIcB9QzYLwRE0RZUgoOlIhsNqEPQtyMCtH0D1nPJlbOpuC1C-GPAsRbQ7wuh1xdP-mPz76R7MNt8aLdo66pzswVziKr8vJ5sGyrD_kjswPSAj3a1gn4C27rk1g |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB50F8QX76OeVUR8qbTbNm3xSdxd76J4voW0SRYRW9kLf76T9EBBQfCthWkIk5nJN5npF4A9zHkCnqQEkVuCCUrY4lZi-75FCBpAy_ZkKtWZ7tldED-H7Y6iyTmq_oUp-CHqAzflGTpeKwd_5_Krk_PxoYMWSSah6SEMV8T5rntTh2GEOjoMRy1iKVKtklZIt_FUn37bjJpKrx8_Ic3vwFXvPN3Zf815DmZKwGkeFxYyDxMiW4Cp67Kkvgidbj9_MxFcm7p8nfUG5ktmsjQTprqtOO-pYPgyMIe5Fqo4yIUWq9vUl-Ch27k_ObPKuxWs1I1CYiGKShMmmR9Kj7HAj_Al4C5mWzJxZEpC1baRCB45MgpkGAnpOtIWqWczVZgU7jI0sjwTq2ByN7SlbYtWwjDZFgQBV8pxEIR2AXMiZsBupWT6XlBo0Dr14GOqFWLAvlZ_LcH6r6rnLPDpU3xKH-PbK4SGAfUM2KnWh6InqPIGy0Q-GlCHYGRH_Gf7BqwUC1ePprK2CMGPAQd6fX6fCL1oP-qHtb-LbsPUTbtLr87jy3WYRkjlF81kG9AY9kdiEyYHfLSlzfMTJ4_jfA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=From+new+findings+in+acne+pathogenesis+to+new+approaches+in+treatment&rft.jtitle=Journal+of+the+European+Academy+of+Dermatology+and+Venereology&rft.au=Gollnick%2C+H.+P.+M.&rft.date=2015-06-01&rft.issn=0926-9959&rft.eissn=1468-3083&rft.volume=29&rft.spage=1&rft.epage=7&rft_id=info:doi/10.1111%2Fjdv.13186&rft.externalDBID=10.1111%252Fjdv.13186&rft.externalDocID=JDV13186 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0926-9959&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0926-9959&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0926-9959&client=summon |